To determine therapeutic potential of Pd‐In on AD, four‐month‐old APP/PS1 transgenic mice with 5 familial AD mutations (5×FAD) mice were intravenously administrated with either 250 μL Pd‐In (1.2 mg/mL), insulin (1.17 mg/mL), or phosphate‐buffered saline (PBS) every three days. This evidence concerns the gene APP and Alzheimer disease.